2022 年 4 月至 2023 年 1 月对尼日利亚艾滋病病毒感染者进行 SARS-CoV-2 血清学监测。

IF 4.8 2区医学 Q1 INFECTIOUS DISEASES

International Journal of Infectious Diseases Pub Date : 2025-02-01 DOI:10.1016/j.ijid.2024.107309

Helen M. Chun , Sophia Osawe , Samuel Adams-Dabban , Jennifer Favaloro , Nnaemeka C. Iriemenam , Emilio Dirlikov , Diana Martin , Kyle Milligan , Andrew Abutu , Olumide Okunoye , Mary Okoli , Olusola Akanbi , Oluwaseun Akinmulero , Rita Okonkwo , Oyewole Oyedele , Stacie Greby , Alash'le Abimiku , McPaul I.J. Okoye , Ray W. Shiraishi , Ijeoma Ezeuko

{"title":"2022 年 4 月至 2023 年 1 月对尼日利亚艾滋病病毒感染者进行 SARS-CoV-2 血清学监测。","authors":"Helen M. Chun , Sophia Osawe , Samuel Adams-Dabban , Jennifer Favaloro , Nnaemeka C. Iriemenam , Emilio Dirlikov , Diana Martin , Kyle Milligan , Andrew Abutu , Olumide Okunoye , Mary Okoli , Olusola Akanbi , Oluwaseun Akinmulero , Rita Okonkwo , Oyewole Oyedele , Stacie Greby , Alash'le Abimiku , McPaul I.J. Okoye , Ray W. Shiraishi , Ijeoma Ezeuko","doi":"10.1016/j.ijid.2024.107309","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria.</div></div><div><h3>Methods</h3><div>We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status.</div></div><div><h3>Results</h3><div>Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex.</div></div><div><h3>Conclusion</h3><div>High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.</div></div>","PeriodicalId":14006,"journal":{"name":"International Journal of Infectious Diseases","volume":"151 ","pages":"Article 107309"},"PeriodicalIF":4.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023\",\"authors\":\"Helen M. Chun , Sophia Osawe , Samuel Adams-Dabban , Jennifer Favaloro , Nnaemeka C. Iriemenam , Emilio Dirlikov , Diana Martin , Kyle Milligan , Andrew Abutu , Olumide Okunoye , Mary Okoli , Olusola Akanbi , Oluwaseun Akinmulero , Rita Okonkwo , Oyewole Oyedele , Stacie Greby , Alash'le Abimiku , McPaul I.J. Okoye , Ray W. Shiraishi , Ijeoma Ezeuko\",\"doi\":\"10.1016/j.ijid.2024.107309\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><div>Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria.</div></div><div><h3>Methods</h3><div>We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status.</div></div><div><h3>Results</h3><div>Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex.</div></div><div><h3>Conclusion</h3><div>High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.</div></div>\",\"PeriodicalId\":14006,\"journal\":{\"name\":\"International Journal of Infectious Diseases\",\"volume\":\"151 \",\"pages\":\"Article 107309\"},\"PeriodicalIF\":4.8000,\"publicationDate\":\"2025-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1201971224003850\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1201971224003850","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

摘要

目标：有证据表明，艾滋病毒感染者（PLHIV）受 COVID-19 的影响更大。尼日利亚艾滋病毒携带者感染 SARS-CoV-2 的情况尚不清楚：我们在尼日利亚 14 个州和联邦首都区对 2022 年 4 月至 2023 年 1 月期间接受过 HIV 病毒载量 (VL) 检测的 PLHIV 进行了重复横断面 SARS-CoV-2 血清调查。使用多重串珠检测法（MBA）评估 SARS-CoV-2 免疫球蛋白 G (IgG) 抗体的证据，检测 IgG 与尖峰蛋白 (S)、受体结合域 (RBD) 和核壳蛋白 (N) 的结合情况，以确定潜在的感染和/或疫苗接种状况：结果：2022 年 4 月至 2023 年 1 月期间，47,614 份残余 VL 样本被纳入并进行了 SARS-CoV-2 抗体检测。SARS-CoV-2感染的血清流行率（定义为尖头抗体和RBD591[S+]及核头壳[N+]的IgG抗体）从2023年1月埃基蒂州的21-1%（95% CI：11-4-31-8）到2022年11月贡贝州的71-4%（95% CI：71-9-81-9）不等，随着时间的推移，州内和各州之间在年龄和性别方面总体呈稳定趋势：结论：在尼日利亚的艾滋病毒携带者中，SARS-CoV-2 抗体血清阳性反应率很高。这突出表明，有必要了解艾滋病毒与 SARS-CoV-2 之间的关联，以便为减少 COVID-19 带来的威胁的战略提供信息。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023

Objectives

Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria.

Methods

We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status.

Results

Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex.

Conclusion

High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Infectious Diseases 医学-传染病学

CiteScore

18.90

自引率

2.40%

发文量

1020

审稿时长

30 days

期刊介绍： International Journal of Infectious Diseases (IJID) Publisher: International Society for Infectious Diseases Publication Frequency: Monthly Type: Peer-reviewed, Open Access Scope: Publishes original clinical and laboratory-based research. Reports clinical trials, reviews, and some case reports. Focuses on epidemiology, clinical diagnosis, treatment, and control of infectious diseases. Emphasizes diseases common in under-resourced countries.